Royalty Pharma PLC (NASDAQ:RPRX) Shares Acquired by KBC Group NV

KBC Group NV raised its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 43.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,405 shares of the biopharmaceutical company's stock after purchasing an additional 17,851 shares during the period. KBC Group NV's holdings in Royalty Pharma were worth $1,849,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. raised its stake in Royalty Pharma by 42.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock valued at $432,862,000 after buying an additional 5,069,127 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Royalty Pharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 7,312,551 shares of the biopharmaceutical company's stock worth $186,846,000 after acquiring an additional 46,765 shares in the last quarter. Norges Bank acquired a new stake in shares of Royalty Pharma during the 4th quarter worth about $124,498,000. Two Sigma Advisers LP raised its position in shares of Royalty Pharma by 21.1% during the 4th quarter. Two Sigma Advisers LP now owns 3,673,200 shares of the biopharmaceutical company's stock worth $93,703,000 after acquiring an additional 640,000 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Royalty Pharma by 12.8% during the fourth quarter. Northern Trust Corp now owns 3,330,429 shares of the biopharmaceutical company's stock worth $84,959,000 after purchasing an additional 376,619 shares in the last quarter. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Finally, Morgan Stanley assumed coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average price target of $47.33.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock traded down $0.78 during trading on Monday, reaching $35.59. The company's stock had a trading volume of 3,328,035 shares, compared to its average volume of 3,678,121. The company has a 50-day moving average price of $33.94 and a two-hundred day moving average price of $32.11. The firm has a market cap of $20.01 billion, a PE ratio of 19.24, a P/E/G ratio of 1.87 and a beta of 0.50. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $36.43. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.68.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to analysts' expectations of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. On average, analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date was Friday, May 16th. Royalty Pharma's payout ratio is currently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.